Skip to main content
. 2016 Mar 14;7(16):22752–22769. doi: 10.18632/oncotarget.8045

Figure 3. Association between TMPRSS4 promoter methylation status and RFS in NSCLC patients.

Figure 3

The previously defined 50% methylation cutoff value (β<0.5) was used to categorize patients into two groups (high and low methylation status). The following probes were depicted in ADC and SCC graphics, respectively: CG27300950 A-B. CG25116503 C-D. CG22957898 E-F. and CG05416223 G-H. Significant reduction in RFS was found for SCC patients with low TMPRSS4 promoter methylation in 3 out of 4 CpGs analyzed. Only CG27300950 was significantly different between groups in ADC and close to statistical significance in SCC.